Day 2 Program

Poster Spotlight 3: HER2 Positive 

Day 2: December 9, 2026

7:00 AM–8:30 AM CST

301 ABC

Session Details

Moderator

Ian Krop

PS3-1

A Phase 1 study of IKS014 (caxmotabart entudotin) in patients with HER2+ solid tumors, and preliminary activity in breast cancer patients previously treated with trastuzumab deruxtecan

Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA

PS3-2

Disitamab vedotin in HER2-low and -ultralow advanced breast cancer: a prospective, phase 2, two-center clinical trial

Wenjin Yin, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

PS3-3

Efficacy and safety of TQB2102, a bispecific HER2 antibody-drug conjugate, in patients with HER2 immunohistochemistry 0 metastatic breast cancer: a multicenter, single-arm, phase 2 trial

Xiaosong Chen, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

PS3-4

Efficacy and safety of JNJ-95310683 (ARX788), an anti-HER2 antibody drug conjugate (ADC), multiply pre-treated in patients (pts) with HER2+ unresectable or metastatic breast cancer (mBC): primary results of the phase 2 ACE-Breast-03 trial

Adrienne G. Waks, Dana Farber Cancer Institute, Boston, MA

PS3-5

HER2DX ERBB2 mRNA Expression Predicts Clinical Benefit from Trastuzumab Deruxtecan in Advanced Breast Cancer: The HER2-PREDICT (SOLTI-1804) Study)

Tomás Pascual, Clinic Barcelona Comprehensive Cancer Center/Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute/Medicine Department, University of Barcelona/SOLTI Cancer Research Group, Barcelona, Spain

PS3-6

Discussant

Funda Meric-Bernstam, UT MD Anderson Cancer Center, Houston, TX

PS3-7

Clinical efficacy of zongertinib monotherapy in HER2-mutant metastatic breast cancer

David Berz, Valkyrie Clinical Trials, Los Angeles, CA

PS3-8

Zanidatamab + palbociclib (PAL) + fulvestrant (FUL) in patients (pts) with hormone receptor-positive (HR+)/HER2-positive (HER2+) metastatic breast cancer (mBC): Final results and biomarker analyses from a phase 2a trial

Santiago Escrivá-de-Romani, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona, Spain

PS3-9

Zanidatamab (ZW25) combined with tucatinib in patients with HER2-positive metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial

Jason Mouabbi, University of Texas MD Anderson Cancer Center, Houston, TX

PS3-10

Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer (MBC)

Hyo Sook Han, Moffitt Cancer Center, Tampa, FL

PS3-11

Whole-body ABS011 HER2 PET complements tissue biopsy through non-invasive mapping of HER2 heterogeneity: Interim results from the HERMIA study.

Evandro de Azambuja, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), Bruxelles, Belgium